Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

Abstract

These results support the potential interest of IP rIFN-gamma as adjuvant treatment in ovarian cancer. Controlled prospective trials are required to determine its place in the therapeutic strategy of this malignancy.